China Resources Shuanghe: Subsidiary DC6001 receives approval for clinical trials.

Announcement from China Resources Shuanghe: its wholly-owned subsidiary Beijing Shuanghe Runchuang Technology Co., Ltd. has received the Drug Clinical Trial Approval Notice for the DC6001 tablet from the National Medical Products Administration. The DC6001 tablet is intended for use in genetic macular degeneration in adolescents, with a total research and development investment of RMB 14.897 million. As of the date of this announcement, the company's cumulative research and development investment for this drug is RMB 14.897 million.